- Home
- CMPX vs FLC Comparison
CMPX vs FLC Comparison
Compare CMPX & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- FLC
- Stock Information
- Founded
- CMPX 2014
- FLC 2003
- Country
- CMPX United States
- FLC United States
- Employees
- CMPX N/A
- FLC N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- CMPX Health Care
- FLC Finance
- Exchange
- CMPX Nasdaq
- FLC Nasdaq
- Market Cap
- CMPX 217.4M
- FLC 168.0M
- IPO Year
- CMPX N/A
- FLC N/A
- Fundamental
- Price
- CMPX $1.54
- FLC $17.00
- Analyst Decision
- CMPX Strong Buy
- FLC
- Analyst Count
- CMPX 2
- FLC 0
- Target Price
- CMPX $9.00
- FLC N/A
- AVG Volume (30 Days)
- CMPX 370.5K
- FLC 37.8K
- Earning Date
- CMPX 11-07-2024
- FLC 01-01-0001
- Dividend Yield
- CMPX N/A
- FLC 6.64%
- EPS Growth
- CMPX N/A
- FLC N/A
- EPS
- CMPX N/A
- FLC N/A
- Revenue
- CMPX $850,000.00
- FLC N/A
- Revenue This Year
- CMPX N/A
- FLC N/A
- Revenue Next Year
- CMPX $950.68
- FLC N/A
- P/E Ratio
- CMPX N/A
- FLC N/A
- Revenue Growth
- CMPX N/A
- FLC N/A
- 52 Week Low
- CMPX $0.77
- FLC $12.62
- 52 Week High
- CMPX $2.34
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- CMPX 64.03
- FLC 72.97
- Support Level
- CMPX $1.42
- FLC $16.79
- Resistance Level
- CMPX $1.65
- FLC $16.96
- Average True Range (ATR)
- CMPX 0.13
- FLC 0.14
- MACD
- CMPX 0.01
- FLC -0.00
- Stochastic Oscillator
- CMPX 66.01
- FLC 90.18
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.